688166 博瑞医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,223,640-4.59%1,179,5181,017,3311,052,409785,383
减:营业总成本1,204,3419.23%980,323783,331789,486598,406
    其中:营业成本601,61210.40%521,414376,299460,671353,994
               财务费用52,22527.66%24,1409,8005,7404,713
               资产减值损失(17,498)-12.26%(21,490)(14,649)(9,396)(9,395)
公允价值变动收益13,785-341.85%(520)(3,395)79044
投资收益(19,321)66.08%(14,741)3,9579,2313,547
    其中:对联营企业和合营企业的投资收益(12,617)37.72%(13,605)(8,917)(9,236)(2,243)
营业利润14,664-90.85%190,244242,155258,991193,064
利润总额13,909-91.15%188,770242,207257,455191,321
减:所得税费用(23,045)-244.60%15,34630,78019,89721,959
净利润36,954-73.84%173,424211,427237,558169,362
减:非控股权益(17,560)-63.34%(29,042)(28,196)(6,393)(521)
股东净利润54,515-71.18%202,466239,623243,951169,882

市场价值指针
每股收益 (元) *0.130-71.11%0.4800.5800.6000.410
每股派息 (元) *0.016-83.33%0.0960.1140.1200.084
每股净资产 (元) *5.8145.92%5.4285.0094.0933.492
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容